Search

everythinglearnresearchcommunity

for

Search:↓

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Some COVID-19 patients have skin issues, with men, ICU patients, and those on multiple antibiotics at higher death risk; in-person skin checks by dermatologists are more effective.

Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.

About 61% of women who had COVID-19 experienced hair loss afterward.

Many survivors of critical illness, especially those with sepsis, experience hair loss.

The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.

After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.

Most hospitalized COVID-19 patients had long-term symptoms like fatigue and hair loss, with women and those sicker during hospitalization at higher risk.

Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.

Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

Possible link between androgens and COVID-19 severity; more research needed.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

Diuretics can cause serious side effects and should be used carefully.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Higher dihydrotestosterone may be linked to more inflammation in COVID-19 patients with low testosterone.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.

People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.

Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.

The document concludes that managing PCOS involves treating symptoms, regulating periods, and reducing health risks, with specific medications for fertility and metabolic issues.

Dermatologists helped identify COVID-19 through skin symptoms and managed skin issues during the pandemic, but more high-quality research is needed.

The conclusion is that certain genetic factors and blood types may affect COVID-19 severity, but changes in ACE2 and TMPRSS2 genes are not clearly linked to it.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.